Detalhe da pesquisa
1.
Target-Mediated Drug Disposition Affects the Pharmacokinetics of Interleukin-10 Fragment Crystallizable Fusion Proteins at Pharmacologically Active Doses.
Drug Metab Dispos
; 50(7): 898-908, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35545256
2.
Characterization of Mauritian Cynomolgus Macaque FcγR Alleles Using Long-Read Sequencing.
J Immunol
; 202(1): 151-159, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30530595
3.
Role of FcγRs in Antibody-Based Cancer Therapy.
Curr Top Microbiol Immunol
; 423: 13-34, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30790079
4.
In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
Clin Cancer Res
; 15(10): 3376-83, 2009 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19401346
5.
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
Cancer Immunol Res
; 7(10): 1633-1646, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31431433
6.
Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy.
Sci Adv
; 5(2): eaav2437, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30801016
7.
Hydrogen/deuterium exchange mass spectrometry and computational modeling reveal a discontinuous epitope of an antibody/TL1A Interaction.
MAbs
; 10(1): 95-103, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29135326
8.
The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.
Oncoimmunology
; 6(9): e1339853, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28932638
9.
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
Cancer Immunol Res
; 5(2): 106-117, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28073774
10.
PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.
Blood Adv
; 1(12): 753-765, 2017 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29296719
11.
Development of antibody-targeted vaccines.
Curr Opin Mol Ther
; 7(2): 157-63, 2005 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15844624
12.
A two-component modular approach for enhancing T-cell activation utilizing a unique anti-FcgammaRI-streptavidin construct and microspheres coated with biotinylated-antigen.
Biomol Eng
; 20(1): 21-33, 2003 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12485681
13.
Chemical production of bispecific antibodies.
Methods Mol Biol
; 283: 71-85, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15197303
14.
Direct targeting of genetically modified tumour cells to Fc gammaRI triggers potent tumour cytotoxicity.
Br J Haematol
; 132(3): 317-25, 2006 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-16409296
15.
Enhanced antigen-specific antibody and cytokine responses when targeting antigen to human FcGAMMA receptor type I using an anti-human FcGAMMA receptor type I-streptavidin fusion protein in an adjuvant-free system.
Immunol Invest
; 34(4): 417-29, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16304730
16.
Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.
J Infect Dis
; 191(4): 507-14, 2005 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15655773
17.
Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques.
J Immunol
; 171(11): 6251-9, 2003 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14634142
18.
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.
Blood
; 102(10): 3737-42, 2003 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12881320